BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 5 September 1997.
Texas Applied Biotechnology Services president, Ms. Joyce Heinrich, informed Robinson that the prototype syringe would be available for preliminary evaluation of the patented working mechanics of the syringe next week. "This is exciting news, to see a dream become a reality. This moves Maxxon to the next level of its rapid growth," said Robinson.
In informal interviews with medical officials around the country it was confirmed that syringes of the type being designed by Maxxon Inc., can play a significant role in the reduction of transmission of HIV and the AIDS virus, in addition to all other diseases that are transmittable through hypodermic needles. Additionally, they commented that Maxxon's one-handed technique should help reduce needlestick accidents in the medical and healthcare industry as a whole.
Maxxon Inc. is an innovative medical technologies company offering cutting edge solutions. The Maxxon Safety Syringe(TM), which meets all OSHA standards, is expected to save hundreds of lives annually. According to estimates of project engineers, the Maxxon Safety Syringe(TM) can be produced for costs that are competitive with safety and non-safety syringes currently in use.
The company plans to market the Maxxon Safety Syringe(TM) internationally, which accounts for 80% of the total market for syringes, while awaiting FDA approval for distribution in the U.S. The work marketplace is estimated to be 15 billion units annually.
--30--SH/dx*
CONTACT: Maxxon Inc., Tulsa William Robinson, 888/492-1257 or CFBR Todd Hickman, 281/370-2544
Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970905
BW970902
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .